dasatinib sandoz 50 mg film-coat. tabl.
sandoz sa-nv - dasatinib 50 mg - film-coated tablet - 50 mg - dasatinib 50 mg - dasatinib
dasatinib sandoz 70 mg film-coat. tabl.
sandoz sa-nv - dasatinib 70 mg - film-coated tablet - 70 mg - dasatinib 70 mg - dasatinib
dasatinib sandoz 100 mg film-coat. tabl.
sandoz sa-nv - dasatinib 100 mg - film-coated tablet - 100 mg - dasatinib 100 mg - dasatinib
dasatinib teva 20 mg film-coat. tabl.
teva b.v. - dasatinib monohydrate 20,739 mg - eq. dasatinib 20 mg - film-coated tablet - 20 mg - dasatinib monohydrate 20.739 mg - dasatinib
dasatinib teva 50 mg film-coat. tabl.
teva b.v. - dasatinib monohydrate 51,847 mg - eq. dasatinib 50 mg - film-coated tablet - 50 mg - dasatinib monohydrate 51.847 mg - dasatinib
dasatinib teva 70 mg film-coat. tabl.
teva b.v. - dasatinib monohydrate 72,585 mg - eq. dasatinib 70 mg - film-coated tablet - 70 mg - dasatinib monohydrate 72.585 mg - dasatinib
dasatinib teva 100 mg film-coat. tabl.
teva b.v. - dasatinib monohydrate 103,693 mg - eq. dasatinib 100 mg - film-coated tablet - 100 mg - dasatinib monohydrate 103.693 mg - dasatinib
dasatinib s.k. 100 mg
k.s.kim international (sk- pharma) ltd., israel - dasatinib - film coated tablets - dasatinib 100 mg - dasatinib - dasatinib is indicated for the treatment of adult patients with:• newly diagnosed philadelphia-chromosome-positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase;• chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib mesilate;• ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy.
dasatinib s.k. 140 mg
k.s.kim international (sk- pharma) ltd., israel - dasatinib - film coated tablets - dasatinib 140 mg - dasatinib - dasatinib is indicated for the treatment of adult patients with:• newly diagnosed philadelphia-chromosome-positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase;• chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib mesilate;• ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy.
dasatinib s.k. 20 mg
k.s.kim international (sk- pharma) ltd., israel - dasatinib - film coated tablets - dasatinib 20 mg - dasatinib - dasatinib is indicated for the treatment of adult patients with:• newly diagnosed philadelphia-chromosome-positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase;• chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib mesilate;• ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy.